BioXcel Therapeutics Inc (NASDAQ:BTAI) closed Friday at $3.03 per share, up from $2.97 a day earlier. While BioXcel Therapeutics Inc has overperformed by 2.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BTAI fell by -85.65%, with highs and lows ranging from $34.12 to $2.23, whereas the simple moving average fell by -72.72% in the last 200 days.
On August 15, 2023, Mizuho Downgraded BioXcel Therapeutics Inc (NASDAQ: BTAI) to Neutral.
Analysis of BioXcel Therapeutics Inc (BTAI)
Further, the quarter-over-quarter increase in sales is 148.91%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of BioXcel Therapeutics Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -489.95% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.45, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and BTAI is recording an average volume of 3.10M. On a monthly basis, the volatility of the stock is set at 6.07%, whereas on a weekly basis, it is put at 5.30%, with a loss of -6.48% over the past seven days. Furthermore, long-term investors anticipate a median target price of $10.80, showing growth from the present price of $3.03, which can serve as yet another indication of whether BTAI is worth investing in or should be passed over.
How Do You Analyze BioXcel Therapeutics Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 30.93%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 35.18% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in BTAI shares?
The recent increase in stakes in BTAI appears to be a result of several institutional investors and hedge funds increasing their positions. Fidelity Management & Research Co’s position in BTAI has decreased by -38.25% in the first quarter. The company now owns 2,700,727 shares of the stock, with a value of $10.26 million, following the sale of -1,672,720 additional shares during the last quarter. BlackRock Fund Advisors made another decreased to its shares in BTAI during the first quarter, downing its stake by -1.91%. During the last quarter, the company picked up -23,116 additional shares for a total stake of worth $4.5 million, bringing number of shares owned by the company to 1,184,506.
During the first quarter, The Vanguard Group, Inc. added a 91,600 position in BTAI. Columbia Management Investment Ad purchased an additional 0.32 million shares in the last quarter, increasing its holdings by 91.26%, now holding 0.67 million shares worth $2.54 million. BTAI shares are owned by institutional investors to the tune of 35.18% at present.